Business Wire

Mavenir Proves AMD Technology across its Open RAN OpenBeam™ Radio and Converged Packet Core Portfolio

1.2.2023 17:00:00 EET | Business Wire | Press release

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud, today announced new initiatives in collaboration with AMD to help Communication Service Providers (CSPs) in their transition to cloud-native telecommunication networks.

First, Mavenir and AMD have been collaborating in Open RAN to build industry leading radio technology. Mavenir has incorporated the AMD Zynq™ Ultrascale+™ RFSoC devices into Mavenir’s OpenBeam™ Radio Portfolio and, through this partnership, both companies continue to work together to introduce new functionality, features, and capabilities to customers.

Secondly, Mavenir’s Converged Packet Core has been validated on AMD EPYC™ CPUs – This means Mavenir’s cloud-native, fully containerized, virtualized Converged Packet Core (4G & 5G) solution can now be deployed on AMD EPYC server CPUs to provide CSPs with more options to implement virtual network functions in cloud data centers.

The elements validated include AMF, SMF, UPF, UDSF, NRF, NSSF, AUSF, UDM, and UDR network functions. Additionally, PCF, NEF, BSF, MME, SecGw, PCRF, MME and SGSN network functions will be validated in the coming months.

“Mavenir’s commitment to enabling networks built on software that runs on any cloud revolves around giving CSPs the ability to use the best components that fit their specific needs, in the cell-site and in the data center,” said Bejoy Pankajakshan, EVP, Chief Technology and Strategy Officer, Mavenir. “Mavenir and AMD are working together to give CSPs multiple options and help them optimize power consumption, network efficiency and total cost of ownership in the radio access as well as the core network.”

“Cloud-native telecom networks empower CSPs with systems that offer flexibility, lower operational cost, ease of system management, and a broader ecosystem for value add, innovation, and upgrade capabilities as network requirements grow,” said Salil Raje, senior vice president and general manager, Data Center and Communications Group, AMD. “We are extremely proud of our close collaboration with Mavenir to help deliver exceptional TCO and predictable scalability along with high performance and power efficient solutions to telecommunications operators leveraging AMD data center products.”

Mavenir’s OpenBeam innovative radio portfolio is specifically designed for the growing needs of CSPs with agile, cost-efficient, intelligent radios to meet critical demands on the network now, and as the network changes and expands. The radio solutions can be used for a wide range of use cases, including basic coverage across all frequency bands, outdoor small cells, for public and private networks providing business and consumer services in both urban and rural environments.

Mavenir’s Converged Packet Core is an end-to-end, fully containerized portfolio that offers multi-generational support to modernize existing mobile networks while providing a cost-effective journey to 5G. Its cloud-native architecture, with applications and services purpose-built for the cloud model, offers easy scaling, hardware decoupling, agility, portability and resiliency across public, private and hybrid clouds. Its web-scale granular microservice architecture meets carrier-grade requirements such as high availability, security, and performance.

To know more about the joint collaboration, visit Mavenir (hall 2 stand 2H60) and AMD (hall 2 stand 2M61) at Mobile World Congress 2023 in Barcelona (February 27th – March 2nd).

AMD, the AMD Arrow logo, EPYC™, Zynq™ and Ultrascale+™, and combinations thereof, are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contact:
PR@mavenir.com

Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye